不适合移植的多发性骨髓瘤患者结局与治疗实施的临床预测模型(英国骨髓瘤研究联盟风险评分):开发与验证研究
研究利用NCRI Myeloma XI(n=1852)和MRC Myeloma IX(n=520)两项随机对照试验中不适合干细胞移植的新诊断多发性骨髓瘤患者数据,开发并验证了英国骨髓瘤研究联盟风险评分(MRP)用于预测总生存。MRP纳入WHO体能状态、国际分期系统、年龄和C反应蛋白浓度,在NCRI-XI内部验证和MRC-IX外部验证中均显示预后价值(D统计量分别为0.840和0.654)。
要点
- MRP纳入WHO体能状态、国际分期系统、年龄和C反应蛋白浓度作为预后变量。
- MRP在NCRI-XI内部验证和MRC-IX外部验证中均对总生存有预后价值。
- MRP低、中、高危分组与无进展生存和早期死亡率相关。
核心结论
- 开发并外部验证了一个包含广泛可用临床参数的总生存风险评分,可辅助不适合干细胞移植的多发性骨髓瘤患者的决策,但需要进一步外部验证。
研究设计与样本
- 使用NCRI Myeloma XI研究(n=1852)和MRC Myeloma IX研究(n=520)中不适合干细胞移植的新诊断多发性骨髓瘤患者数据,开发并验证MRP。
- 采用带最小绝对收缩和选择算子惩罚项的多变量Cox回归,并使用链式方程多重插补处理缺失数据。
- MRP在NCRI-XI中内部验证,在MRC-IX中外部验证,并依据预设标准估计D统计量。
主要发现
- MRP纳入WHO体能状态、国际分期系统、年龄和C反应蛋白浓度作为预后变量。
- MRP对总生存有预后价值,内部验证D统计量NCRI-XI为0.840(95%CI 0.718-0.963),外部验证D统计量MRC-IX为0.654(95%CI 0.497-0.811)。
- MRP定义的低危、中危和高危分组与无进展生存和早期死亡率相关。
- 方案剂量交付百分比下降和基线生活质量与风险增加相关。
- MRP分组在不同治疗组合暴露患者以及根据英国和国际骨髓瘤工作组定义遗传高风险疾病患者中仍保持预后价值。
关键数值与推荐
- MRP包含WHO体能状态、国际分期系统、年龄和C反应蛋白浓度。
- 内部验证D统计量NCRI-XI为0.840(95%CI 0.718-0.963),外部验证D统计量MRC-IX为0.654(95%CI 0.497-0.811)。
临床怎么用
- 作者认为该风险评分可辅助不适合干细胞移植的多发性骨髓瘤患者的决策,但需要进一步外部验证。
局限性
- 需要进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantation. METHODS: We used patient data from two randomised controlled trials done in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI, n=1852] and the MRC Myeloma IX study [MRC-IX, n=520]), to develop the UK Myeloma Research Alliance Risk Profile (MRP) for overall survival. We used multivariable Cox regression with a least absolute shrinkage and selection operator penalty term. Multiple imputation by chained equations was used to account for missing data in the development and internal validation of the model. The MRP was internally validated in NCRI-XI and externally validated in MRC-IX. The D-statistic was estimated in the developed model and used to internally and externally validate the model according to prespecified criteria. FINDINGS: The MRP included WHO performance status, International Staging System, age, and C-reactive protein concentration as prognostic variables. The MRP was prognostic of overall survival and was successfully internally validated in NCRI-XI and externally validated in MRC-IX (D-statistic NCRI-XI: 0·840 [95% CI 0·718-0·963] and MRC-IX: 0·654 [0·497-0·811]). The MRP groups defining low-risk, medium-risk, and high-risk patients were associated with progression-free survival and early mortality. A decrease in the percentage of protocol dose delivered and quality of life at baseline were associated with increased risk. The MRP groups remained prognostic in patients exposed to different therapeutic combinations and in patients with genetic high-risk disease defined according to both the UK and International Myeloma Working Group definitions. INTERPRETATION: We have developed and externally validated a risk profile for overall survival containing widely available clinical parameters. This risk profile could aid decision making in patients with multiple myeloma ineligible for stem-cell transplantation, but further external validation is required. FUNDING: Medical Research Council, Novartis, Schering Health Care, Chugai, Pharmion, Celgene, Ortho Biotech, Cancer Research UK, Celgene, Merck Sharp & Dohme, and Amgen.
引用
- Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019. PMID: 30738834. doi:10.1016/S2352-3026(18)30220-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。